# TACT (NCT05024266)

> Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: tislelizumab plus albumin paclitaxel plus carboplatin
- Indication: stage IIIA-IIIB (N2) lung squamous cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05024266
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: First Affiliated Hospital of Zhejiang University
- Conditions: Lung Squamous Cell Carcinoma; Neoadjuvant Therapy; Immunotherapy
- Interventions: Tislelizumab
- Enrollment: 30
- Primary outcome: Major Pathological Response (MPR)
- Primary outcome: Incidence of Treatment-Emergent Adverse Events

## Indexed commentary on TACT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 16
- YouTube: 6
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=tact-nct05024266

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05024266", "email": "<work email>"}; the inbox owner confirms by the emailed link.